Health Economics›Peripheral T-cell lymphoma›Untreated non-randomized or retrospective data

Untreated non-randomized or retrospective data

Peripheral T-cell lymphoma · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
A-CHOP Variant #01	—	R 76 309	28d	—	—	—	—	—
CHOP and Everolimus Variant #01	—	R 5 461	21d	—	—	—	—	—
CHOEP-14 Variant #01	—	R 1 887	14d	—	—	—	—	—
DA-EPOCH Variant #01	—	R 1 522	21d	—	—	—	—	—
DD-CHOP Variant #01	—	R 872	21d	—	—	—	—	—
HyperCHidam Variant #01	—	R 55	—	—	—	—	—	—

6 of 6 regimens shown